Revenue: As of FY2025 Q3, the actual value is USD 2.264 M.EPS: As of FY2025 Q3, the actual value is USD 0.06.EBIT: As of FY2025 Q3, the actual value is USD 139.91 K.<h3>Segment Revenue</h3><ul><li>Cosmetic Ingredients: Sales decreased by $886,186 (69%) in Q3 2025 compared to Q3 2024, primarily due to decreased sales to ASI and economic conditions in China.</li><li>Pharmaceuticals: Gross sales increased by $146,849 (11%) in Q3 2025, with net sales increasing by $108,080 (10%) due to increased sales of Renacidin.</li><li>Medical Lubricants: Sales decreased by $17,746 (3%) in Q3 2025 compared to Q3 2024, attributed to normal ordering patterns.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: Decreased to $268,441 in Q3 2025 from $865,484 in Q3 2024.</li><li>Operating Expenses: Increased by $29,846 (5%) in Q3 2025 compared to Q3 2024, due to higher sales and marketing expenses, and payroll-related costs.</li><li>Research and Development Expenses: Increased by $6,032 (5%) in Q3 2025 compared to Q3 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Decreased to $1,636,324 for the nine months ended September 30, 2025, from $3,196,954 in the same period in 2024.</li><li>Investing Activities: Provided $115,577 in cash for the nine months ended September 30, 2025, compared to cash used of $6,241,837 in the same period in 2024.</li><li>Financing Activities: Used $2,766,720 in cash for the nine months ended September 30, 2025, compared to $2,756,323 in the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is expanding its distribution network and monitoring its supply chain to control costs. It is also seeking opportunities to expand its position in healthcare and pursuing external growth opportunities.</li><li>Non-Core Business: Manufacturing of the new Natrajel line of sexual wellness ingredients has been delayed until 2026 due to customer timeline adjustments.</li></ul>

United-Guardian | 10-Q: FY2025 Q3 Revenue: USD 2.264 M